EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders

Inclusion Criteria: * Patients who signed the Informed Consent for participation in the observational study before collection of any information * Patients who complain of psycho-emotional disturbance (of any intensity) * Men and women aged 18-45 years, who prescribed to receive Tanakan® for cognitive disorders Exclusion Criteria: * Presence of any contraindications listed in the Tanakan® local SmPC (hypersensitivity to any of the components of Tanakan®, pregnancy, lactation, erosive gastritis in acute phase, gastric ulcer and duodenum ulcer in acute phase, acute cerebrovascular accident, acute myocardial infarction, congenital galactosemia, lactase deficiency, glucose-galactose malabsorption, haemolysis) * Presence of dementia (according to Diagnostic and Statistical Manual of Mental Disorders \[DSM IV\]) * Disturbance of usual activities of daily living (e.g. self-care) * Patients taking antipsychotic drugs, antidepressants, tranquillisers and nootropic agents * Presence of any severe disease or condition which could affect cognitive function (e.g. Parkinson disease, epilepsy, brain inflammatory disease, major depression, recent post-stroke condition, recent brain-trauma etc.); * Presence of anxiety or depression according to the Hospital Anxiety and Depression Scale (11 points and more).